Urinary Tract Infections Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

  • ID: 4517513
  • Report
  • 145 pages
  • P&S Market Research
1 of 3
Urinary tract infection (UTI) refer to a common bacterial infection disease, that occurs in either a community or healthcare setting. Clinically, UTIs are categorized as uncomplicated and complicated. Uncomplicated UTIs typically occur in a healthy adult non-pregnant woman and have no structural or neurological urinary tract abnormalities; these infections are differentiated into cystitis and pyelonephritis.

UTIs are caused by both gram-negative and gram-positive bacteria, as well as by certain fungi. Gram-negative rod Escherichia coli is the most common cause of UTIs in all settings and is transmitted by person-to-person direct contact and the fecal-oral route. The study analyzed that UTIs therapeutics pipeline comprises approximately 40 drug candidates in different stages of development.

Pipeline Insights

According to the research findings, a majority of the drug candidates for the treatment of UTIs are being developed as small molecules. It has been observed that the drugs that are being developed as small molecules are easy to manufacture with high production rate.

Significant growth due to various technological advancements

It has been observed that a majority of the companies in the UTIs therapeutic pipeline are developing drug candidates by using advanced technologies and these drug candidates have further shown positive efficacy in the clinical stage of development. For instance, MULTIPHORE Drug Design platform developed by Talon Pharmaceuticals Inc., specifies the complexity of the disease in nature. The above-mentioned technology is designed to identify the drug that interacts with multiple disease target through careful incorporation of multiple pharmacophores into a single molecule or through unique combination of different mechanisms of action implicated in the disease state.

The pipeline has more drug candidates being developed as combination therapies

The companies involved in the UTIs therapeutic pipeline are developing various drug candidates as combination therapies, that have several advantages such as, improved medication compliance by decreasing the pill burden of patients, increased efficacy, and reduced side effects and cost. For instance, C-Scape, a Phase I drug candidate by Achaogen Inc. is a combination of ceftibuten and clavulanate, that are small molecules obtained from the synthetic source. Both ceftibuten and clavulanate act by different mechanism of action but give synergistic effects. Ceftibuten acts as cell wall synthesis inhibitor and, clavulanate acts as beta-lactamase inhibitor.

Some of the key players involved in the development of UTIs therapeutics pipeline include Achaogen Inc., AmpliPhi Biosciences Corporation, and Iterum Therapeutics Limited.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 by industry participant
2.2.1.2 by company type

3. Executive Summary

4. Pipeline Outlook
4.1 Disease Overview
4.2 Sign & Symptoms
4.3 Epidemiology
4.4 Diagnosis
4.5 Prevention and Treatment
4.6 Key Drivers
4.6.1 Combination Therapies for Treating UTIs
4.6.2 Technological Advancements
4.7 Key Barriers
4.7.1 Risk Factors Involved in the Treatment of UTIs
4.8 UTIs Therapeutics Pipeline Analysis
4.8.1 Pipeline Analysis by Phase
4.8.2 Pipeline Analysis by Molecule Type
4.8.3 Pipeline Analysis by Route of Administration
4.8.4 Pipeline Analysis by Company

5. UTIs Therapeutics Pipeline Analysis by Phase (2018)
5.1 Filed
5.1.1 Plazomicin
5.1.1.1 Clinical trial
5.1.1.2 Results
5.1.1.3 Strategic development
5.2 Phase III (Expanded Access)
5.2.1 AB-PA01
5.2.1.1 Pre-Clinical studies
5.3 Phase III
5.3.1 MK-7655
5.3.1.1 Clinical trial
5.3.2 XX
5.3.2.1 Clinical trial
5.3.3 XX
5.3.3.1 Clinical trial
5.3.3.2 Clinical results
5.3.3.3 Strategic development
5.3.4 XX
5.3.4.1 Clinical trial
5.3.4.2 Strategic development
5.3.5 XX
5.3.5.1 Clinical trial
5.3.5.2 Strategic development
5.3.6 XX
5.3.6.1 Clinical trial
5.3.6.2 Clinical trial results
5.3.6.3 Strategic development
5.4 Phase II/III
5.4.1 LACTIN-V
5.4.1.1 Clinical trial
5.4.1.2 Clinical result
5.5 Phase II
5.5.1 XX
5.5.1.1 Clinical trials
5.5.1.2 Clinical results
5.5.1.3 Strategic development
5.5.2 XX
5.5.2.1 Clinical trials
5.5.2.2 Strategic development
5.5.3 XX
5.5.3.1 Clinical trials
5.5.3.2 Clinical trial results
5.5.3.3 Strategic development
5.5.4 XX
5.5.4.1 Clinical trials
5.5.5 XX
5.5.5.1 Pre-Clinical results
5.5.5.2 Clinical trials
5.5.5.3 Clinical trial results
5.5.5.4 Strategic development
5.6 Phase I
5.6.1 XX
5.6.2 XX
5.6.2.1 Strategic development
5.6.3 XX
5.6.3.1 Pre-Clinical studies
5.6.3.2 Clinical trials
5.6.3.3 Strategic development
5.6.3.4 Technology
5.6.4 XX
5.6.4.1 Clinical studies
5.6.4.2 Safety results
5.6.4.3 Pharmacokinetics results
5.6.4.4 Final Results
5.6.5 XX
5.6.6 XX
5.6.6.1 Clinical trials
5.6.6.2 Strategic development
5.6.6.3 Technology
5.6.7 XX
5.6.7.1 Clinical trials
5.6.7.2 Clinical results
5.6.7.3 Strategic development
5.6.8 XX
5.6.8.1 Clinical trials
5.6.8.2 Clinical trial results
5.6.8.3 Strategic development
5.6.9 XX
5.6.9.1 Clinical trials
5.6.9.2 Strategic development
5.7 IND
5.7.1 XX
5.7.1.1 Pre-Clinical studies
5.7.1.2 Strategic development
5.8 Pre-Clinical
5.8.1 XX
5.8.1.1 Pre-Clinical studies
5.8.2 XX
5.8.2.1 Pre-Clinical studies
5.8.3 XX
5.8.3.1 Strategic development
5.8.4 XX
5.8.5 XX
5.8.5.1 Pre-Clinical Results
5.8.6 XX
5.8.6.1 Strategic Development
5.8.7 XX
5.8.8 XX
5.8.8.1 Strategic development
5.8.9 XX
5.8.9.1 Strategic development
5.8.10 XX
5.9 Discovery
5.9.1 XX
5.9.2 XX
5.9.2.1 Technology
5.9.3 XX
5.9.4 XX
5.9.4.1 Strategic development
5.9.4.2 Technology
5.9.5 XX
5.1 Unknown
5.10.1 XX
5.10.1.1 Clinical trials

6. Clinical Trials Review
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status

7. Competitive Landscape
7.1 Key Players Benchmarking for UTIs Therapeutics Pipeline
7.2 SWOT Analysis of UTIs Therapeutics Pipeline

8. Company Profiles
8.1 Rebiotix Inc.
8.1.1 Business Overview
8.1.2 Products and Service Offerings
8.2 Company 2
8.2.1 Business Overview
8.2.2 Products and Service Offerings
8.3 Company 3
8.3.1 Business Overview
8.3.2 Products and Service Offerings
8.4 Company 4
8.4.1 Business Overview
8.4.2 Products and Service Offerings
8.5 Company 5
8.5.1 Business Overview
8.5.2 Products and Service Offerings
8.6 Company 6
8.6.1 Business Overview
8.6.2 Products and Service Offerings
8.7 Company 7
8.7.1 Business Overview
8.7.2 Product and Service Offerings
8.8 Company 8
8.8.1 Business Overview
8.8.2 Product and Service Offerings
8.9 Company 9
8.9.1 Business overview
8.9.2 Product and Service Offerings
8.10 Company 10
8.10.1 Business Overview
8.10.2 Product and Service Offerings

9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Table 1 Utis Syndromes: Signs, and Symptoms
Table 2 Pipeline Analysis of Utis Therapeutiscs, by Company (2018)
Table 3 Description of Plazomicin
Table 4 Clinical Trials of Plazomicin
Table 5 Details of Primary End Point 1
Table 6 Details of Primary End Point 2
Table 7 Description of Ab-Pa01
Table 8 Description of Mk-7655
Table 9 Clinical Trials of Mk-7655
Table 10 Description of Xx
Table 11 Clinical Trials of Xx
Table 12 Description of Xx
Table 13 Clinical Trials of Xx
Table 14 Description of Xx
Table 15 Description of Xx
Table 16 Clinical Trials of Xx
Table 17 Description of Xx
Table 18 Clinical Trials of Xx
Table 19 Description of Lactin-V
Table 20 Clinical Trials of Lactin-V
Table 21 Description of Xx
Table 22 Clinical Trials of Xx
Table 23 Description of Xx
Table 24 Clinical Trials of Xx
Table 25 Description of Xx
Table 26 Clinical Trials of Xx
Table 27 Details of Endpoint 1
Table 28 Details of Endpoint 2
Table 29 Details of Endpoint 3
Table 30 Description of Xx
Table 31 Clinical Trials of Xx
Table 32 Description of Xx
Table 33 Description of Xx
Table 34 Description of Xx
Table 35 Description of Xx
Table 36 Description of Xx
Table 37 Description of Xx
Table 38 Description of Xx
Table 39 Clinical Trials of Xx
Table 40 Description of Xx
Table 41 Clinical Trials of Xx
Table 42 Description of Xx
Table 43 Clinical Trials of Xx
Table 44 Description of Xx
Table 45 Clinical Trials of Xx
Table 46 Description of Xx
Table 47 Description of Xx
Table 48 Description of Xx
Table 49 Description of Xx
Table 50 Description of Xx
Table 51 Description of Xx
Table 52 Description of Xx
Table 53 Description of Xx
Table 54 Description of Xx
Table 55 Description of Xx
Table 56 Description of Xx
Table 57 Description of Xx
Table 58 Description of Xx
Table 59 Description of Xx
Table 60 Description of Xx
Table 61 Description of Xx
Table 62 Description of Xx
Table 63 Clinical Trials of Xx
Table 64 Rebiotix Inc. - At a Glance
Table 65 Company 2 - At a Glance
Table 66 Company 3 - At a Glance
Table 67 Company 4 - At a Glance
Table 68 Company 5 - At a Glance
Table 69 Company 6 - At a Glance
Table 70 Company 7 - At a Glance
Table 71 Company 8 - At a Glance
Table 72 Company 9 - At a Glance
Table 73 Company 10 - At a Glance

List of Figures
Fig 1: Research Methodology
Fig 2: Breakdown of Primary Research Respondents, by Industry Participant
Fig 3: Breakdown of Primary Research Respondents, by Company Type
Fig 4: Utis Drug Candidates In Development (2018)
Fig 5: Utis Pipeline Split, by Molecule Type (2018)
Fig 6: Utis Pipeline Split, by Route of Administration (2018)
Fig 7: Breakdown of Clinical Trials, by Region
Fig 8: Breakdown of Clinical Trials, by Trial Status
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll